Clinical Trials on Cholestasis

Total 388 results

Hospital Mutua de Terrassa

Recruiting

Detection Program for Patients With Primary Biliary Cholangitis Lost in the System (RESCAT)

Primary Biliary Cholangitis

Spain
Henning Grønbæk
Aarhus University Hospital; Region Hovedstadens Apotek; Hospitalsapoteket Region... and other collaborators

Recruiting

PBC Induced Fatigue Treated With Thiamine (PIFT)

Primary Biliary Cirrhosis

Denmark
Peking Union Medical College Hospital

Recruiting

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC (UCDA PBC)

Primary Biliary Cholangitis

China
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO)

PBC

France
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Eli Lilly and Company

Terminated

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Primary Biliary Cholangitis

United States, Puerto Rico
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
West China Hospital

Unknown

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Instituto Nacional de Ciencias Medicas y Nutricion...

Unknown

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

Primary Biliary Cirrhosis

Mexico
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Benedetta Terziroli, MD
Intercept Pharmaceuticals; Vifor Pharma; Fondazione Epatocentro Ticino

Completed

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Primary Biliary Cirrhosis

Switzerland
University of Miami
Mayo Clinic

Withdrawn

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
The Cleveland Clinic

Completed

Pentoxifylline for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Geisinger Clinic

Approved for marketing

Compassionate Use of Omegaven

Cholestasis
GlaxoSmithKline

Completed

Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers

Cholestasis

Japan
University Hospital, Toulouse

Terminated

Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region (CHOLESTASE)

Cholestasis

France
Mei Han

Not yet recruiting

Clinical Study on the Treatment of Elevated Total Bilirubin in Primary Biliary Cholangitis With Baobao Dan Capsule

Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

Primary Biliary Cholangitis

China
Kowa Research Institute, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Primary Biliary Cholangitis

United States, Japan
Han Ying

Recruiting

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
CymaBay Therapeutics, Inc.

Recruiting

IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) (IDEAL)

Primary Biliary Cholangitis

United States
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (AFFIRM)

Primary Biliary Cholangitis

United States, Korea, Republic of, Turkey
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Primary Biliary Cholangitis

United States
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Cascade Pharmaceuticals, Inc

Completed

Study of [14C]CS0159 in China Healthy Subjects

Primary Biliary Cholangitis

China
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Cascade Pharmaceuticals, Inc

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

Primary Biliary Cholangitis

China
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Biocad

Terminated

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Liver Cirrhosis, Biliary

Russian Federation
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
SAMEY
Axonal-Biostatem

Unknown

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life (OCARELIFE)

Primary Biliary Cholangitis

France
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
Xijing Hospital of Digestive Diseases

Unknown

Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Mexico
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States

Clinical Trials on Cholestasis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations